Incyte and Mirati Therapeutics, Inc., a clinical-stage targeted oncology company, announced a clinical trial collaboration and supply agreement to investigate a combination of cancer drug candidates.
“While monoclonal antibodies targeting PD‑L1 or PD-1 have transformed the treatment landscape in oncology, they are limited by their route of administration and long-half life and receptor occupancy which can affect the management of immune-related adverse events,” said Lance Leopold, M.D., group vice president, Clinical Development Hematology and Oncology, Incyte. “Incyte’s small molecule, oral PD-L1 program has shown promising safety and efficacy in early studies – (Incyte’s INCB99280’s shorter half life may result in improved management of immune-mediated adverse events and better clinical outcomes.”
“We are pleased to enter into this agreement with Incyte, supplying adagrasib for evaluation in combination with INCB99280,” said Charles Baum, M.D., Ph.D., president, founder and head of research and development at Mirati Therapeutics, Inc. “This agreement is part of our rational combination strategy for adagrasib and further demonstrates our focus to evaluate this asset in a broad range of combinations”, including with novel approaches to checkpoint inhibition, to benefit people living with difficult-to-treat cancers.”
Under the terms of the agreement, Incyte will initiate and sponsor the Phase 1/1b study of INCB99280 and adagrasib in patients with KRAS–mutated solid tumors. Mirati will supply Incyte with adagrasib for the study.
Mirati is based in San Diego, while Incyte’s headquarters is located near Wilmington.
